Patents by Inventor Manuel Modiano

Manuel Modiano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11786504
    Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
    Type: Grant
    Filed: September 9, 2021
    Date of Patent: October 17, 2023
    Assignee: TAPESTRY PHARMACEUTICALS, INC.
    Inventors: James D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
  • Publication number: 20210401797
    Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
    Type: Application
    Filed: September 9, 2021
    Publication date: December 30, 2021
    Applicant: TAPESTRY PHARMACEUTICALS, INC.
    Inventors: James D. MCCHESNEY, Gilles H. TAPOLSKY, David L. EMERSON, John MARSHALL, Michael KURMAN, Manuel MODIANO
  • Patent number: 11147793
    Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubules at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: October 19, 2021
    Assignee: TAPESTRY PHARMACEUTICALS, INC.
    Inventors: James D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
  • Publication number: 20190046501
    Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubules at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
    Type: Application
    Filed: October 12, 2018
    Publication date: February 14, 2019
    Applicant: TAPESTRY PHARMACEUTICALS, INC.
    Inventors: James D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
  • Patent number: 10143677
    Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: December 4, 2018
    Assignee: TAPESTRY PHARMACEUTICALS, INC.
    Inventors: James D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
  • Publication number: 20180117002
    Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
    Type: Application
    Filed: April 10, 2017
    Publication date: May 3, 2018
    Applicant: Tapestry Pharmaceuticals, Inc.
    Inventors: James D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
  • Publication number: 20170273942
    Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
    Type: Application
    Filed: April 10, 2017
    Publication date: September 28, 2017
    Applicant: Tapestry Pharmaceuticals, Inc.
    Inventors: James D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
  • Patent number: 9616043
    Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: April 11, 2017
    Assignee: Tapestry Pharmaceuticals, Inc.
    Inventors: James D. McChesney, Gilles Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
  • Publication number: 20160113898
    Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
    Type: Application
    Filed: September 11, 2015
    Publication date: April 28, 2016
    Applicant: Tapestry Pharmaceuticals, Inc.
    Inventors: James D. McChesney, Gilles Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
  • Patent number: 9132118
    Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: September 15, 2015
    Assignee: Tapestry Pharmaceuticals, Inc.
    Inventors: James D. McChesney, Gilles Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
  • Patent number: 8552056
    Abstract: The present invention relates to a novel chemical compound of formula S-(1): for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.
    Type: Grant
    Filed: September 15, 2012
    Date of Patent: October 8, 2013
    Assignee: Tapestry Pharmaceuticals, Inc.
    Inventors: James D. McChesney, Gilles Tapolsky, David E. Emerson, John Marshall, Tauseef Ahmed, Allen Cohn, Michael Kurman, Manuel Modiano
  • Publication number: 20130253044
    Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
    Type: Application
    Filed: March 5, 2013
    Publication date: September 26, 2013
    Inventors: James D. McChesney, Gilles Tapolsky, David E. Emerson, John Marshall, Tauseef Ahmed, Allen Cohn, Michael Kurman, Manuel Modiano
  • Patent number: 8409574
    Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: April 2, 2013
    Inventors: James D. McChesney, Gilles Tapolsky, David E. Emerson, John Marshall, Tauseef Ahmed, Allen Cohn, Michael Kurman, Manuel Modiano
  • Publication number: 20130022668
    Abstract: The present invention relates to a novel chemical compound of formula S-(1): for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.
    Type: Application
    Filed: September 15, 2012
    Publication date: January 24, 2013
    Applicant: TAPESTRY PHARMACEUTICALS, INC.
    Inventors: James D. McChesney, Gilles TAPOLSKY, David L. EMERSON, John MARSHALL, Tauseef AHMED, Allen COHN, Michael KURMAN, Manuel MODIANO
  • Patent number: 8273789
    Abstract: The present invention relates to a novel chemical compound of formula S-(1): for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: September 25, 2012
    Assignee: Tapestry Pharmaceuticals, Inc.
    Inventors: James D. McChesney, Gilles Tapolsky, David L. Emerson, John Marshall, Tauseef Ahmed, Allen Cohn, Michael Kurman, Manuel Modiano
  • Publication number: 20110318334
    Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
    Type: Application
    Filed: August 20, 2010
    Publication date: December 29, 2011
    Inventors: James D. McChesney, Gilles TAPOLSKY, David L. EMERSON, John MARSHALL, Tauseef AHMED, Allen COHN, Michael KURMAN, Manuel MODIANO
  • Publication number: 20110135712
    Abstract: The present invention relates to a novel chemical compound of formula S-(1): for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.
    Type: Application
    Filed: September 1, 2010
    Publication date: June 9, 2011
    Applicant: TAPESTRY PHARMACEUTICALS, INC.
    Inventors: James D. McChesney, Gilles TAPOLSKY, David E. EMERSON, John MARSHALL, Tauseef AHMED, Allen COHN, Michael KURMAN, Manuel MODIANO